The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with ...

The United Nations Development Programme (UNDP) has announced plans to address the members of Parliament, and parliamentary ...

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

Patients with ARDs who received RTX demonstrated impaired humoral responses to RZV, compared with healthy controls and ...

Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically ...

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma - Monjuvi® (tafasitamab ...

WILMINGTON, Del., June 18, 2025--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic ...

Christina Poh, MD, discusses the recent FDA approval of tafasitamab plus lenalidomide and rituximab in relapsed/refractory ...

Patients receiving Monjuvi in combination with rituximab and lenalidomide achieved a median PFS by investigator assessment of 22.4 months (95% CI, 19.2-not evaluable [NE]) compared to 13.9 months ...

(12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) <li /> EO ...

Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.

An unexpected relapse has columnist Ahna Crum contemplating what remains when the miracle of stem cell transplant seems ...